Abeona Therapeutics reports FY2024 net loss $63.7M, cash $98.1M, pz-cel PDUFA April 29

ABEONA THERAPEUTICS INC.

Net loss of $63.7M ($1.55 per share) for FY2024 vs $54.2M ($2.53 per share) in FY2023.
Cash and investments total $98.1M as of Dec 31, 2024, up from $52.6M; runway into 2026.
FDA PDUFA target action date for pz-cel BLA is April 29, 2025; draft label received March 14.
If approved, first patient treatment with pz-cel expected in Q3 2025; launch prep with five QTCs underway.
Two additional patents for pz-cel extend protection to June 2037 and July 2040.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.